| Objective:(1). To examine that if the soluble programmed death-ligand-1(sPD-L1) is related to EGFR mutation. The associations between the expression level of PD-L1 and clinicopathological features were analyzed statistically.(2). To evaluate that if the expression of PD-L1 in NSCLC cell lines is related to EGFR mutation.Methods:1.Forty-one NSCLC patients with EGFR mutation and thirty-seven NSCLC patients with EGFR wild type ages 45 to 70years( mean age 60 ± 6) were selected from the Department of Respiratory Diseases in Shanxi Tumor hospital, and sixty-eight cases of normal subjects were selected too.All lung cancer patients were newly-diagnosed,treatment-free and confirmed by histopathology or cytopathology. The sPD-L1 protein expression in plasma was determined by ELISA kit(PDCD1LG1 ELISA Kit, USCN Life Science, Wuhan, China).2.Human NSCLC cell lines(H23, A549, H1975) were maintained under humidified atmosphere of 5% CO2 at 37 oC in RPMI 1640 medium, each supplemented with 10%fetal bovine serum. H1975 harbors an activating mutation(L858R) in exon 21 as well as a secondary mutation(T790M) in exon 20; and all other cell lines are wild type for EGFR[14]. Soluble PD-L1 was measured using an enzyme-linked immunosorbent assay(PDCD1LG1 ELISA kit, USCN Life Science, Wuhan, Chain), according to the manufacturer instructions and book.Using SPSS17.0 statistical software to deal with all the clinical data and experimental data.Results:1. Expression of sPD-L1 in patients’ plasma was significantly higher for NSCLC patients with EGFR-mutated than those with EGFR-wild. Expression of sPD-L1 in NSCLC patients was significantly higher than healthy group.2. A higher PD-L1 expression in NSCLC cell lines with activating EGFR mutations than in EGFR wild-type status was detected.Conclusion:sPD-L1 was likely to be associated with NSCLC. The presence of EGFR mutations were significantly associated with increased sPD-L1 in NSCLC. Our results suggested that EGFR and sPD-L1 could be a valuable biomarker in NSCLC EGFR target treatment and PD-L1 immunotherapy treatment in future. |
